Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 16/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24558270 | 0.92 | KRAS (0.45) | KRAS | |
| SCHEMBL31107227 | 0.91 | KRAS (0.49) | KRASCCNT1CDK9 | |
| SCHEMBL24558280 | 0.91 | KRAS (0.49) | KRASCCNT1CDK9 | |
| SCHEMBL24558440 | 0.89 | KRAS (0.61) | KRASCCNT1CDK9 | |
| SCHEMBL31107247 | 0.89 | KRAS (0.61) | KRASCCNT1CDK9 | |
| SCHEMBL31107220 | 0.83 | KRAS (0.45) | KRAS | |
| SCHEMBL29693204 | 0.83 | KRAS (0.45) | KRAS | |
| SCHEMBL24558268 | 0.83 | KRAS (0.45) | KRAS | |
| SCHEMBL24558153 | 0.82 | KRAS (0.40) | KRASUSP30 | |
| SCHEMBL24558262 | 0.82 | KRAS (0.54) | KRASUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | KRAS 89/4885CCNT1 54/4885CDK9 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.